Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China

BACKGROUND: Immune tolerance induction (ITI) therapy is currently unaffordable in China. Management of hemophilia A children with high‐titer inhibitor is therefore a challenge. AIM: To describe the ITI strategy using plasma‐derived factor VIII/von Willebrand factor concentrate (pdFVIII/VWF) +/− immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zekun, Chen, Zhenping, Cheng, Xiaoling, Wu, Xinyi, Li, Gang, Zhen, Yingzi, Cai, Siyu, Poon, Man‐Chiu, Wu, Runhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles: Haemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781932/
https://www.ncbi.nlm.nih.gov/pubmed/31624794
http://dx.doi.org/10.1002/rth2.12248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781932/
https://www.ncbi.nlm.nih.gov/pubmed/31624794
http://dx.doi.org/10.1002/rth2.12248

Ejemplares similares